All Articles

Patients with bladder cancer can be empowered to better cope with their diagnosis by providing them with supplemental information relating to their disease state, potential treatments, and patient support services.

Responses to first- and second-line chemotherapy regimens for metastatic urothelial carcinoma (mUC) have been less than satisfactory, creating an unmet need for new treatment options for this disease.

Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.

The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.

Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States.